IL0011327454 - Common Stock
VASCULAR BIOGENICS LTD
NASDAQ:VBLT (10/16/2023, 7:02:23 PM)
After market: 0.168 +0.01 (+7.69%)0.156
-0.02 (-8.77%)
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. The firm has created a pipeline of therapeutics address cancer and immune-inflammatory diseases with the goal of significantly improving patient outcomes and overcoming the limitations of approved treatments. It's product candidates are built off of two platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications.
VASCULAR BIOGENICS LTD
8 HaSatat St.
Or Yehuda 7178106
P: 97236346450.0
CEO: Dror Harats
Employees: 7
Website: https://www.vblrx.com/
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq...
Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023...
It's time to start the day with a breakdown of the biggest pre-market stock movers that traders will want to watch on Thursday!
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN,...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Here you can normally see the latest stock twits on VBLT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: